Skip to main content
SpringerLink
Log in

Predicting Injection Site Muscle Damage I: Evaluation of Immediate Release Parenteral Formulations in Animal Models

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. The current animal model generally accepted by the pharmaceutical industry and the FDA for assessment of muscle damage following intramuscular injection (IM) is the rabbit lesion volume model (RbLV). However, this model is resource intensive. The goal of this study was to find a resource sparing alternative to the rabbit lesion model for assessing injection site toleration in IM formulation screening.

Methods. Short term animal model alternatives to RbLV for evaluating IM formulations were examined. In addition to RbLV, myeloperoxidase (MPO), p-nitrophenyl N-acetyl-β-glucosaminide (NAβG) and/or plasma creatine phosphokinase (CK) activities were determined in rabbits (Rb) and rats (Rt) after injection of formulations (digoxin, azithromycin and danofloxacin). The edema from these formulations 24 hr after subcutaneous injection into the rat footpad (RFE) was also determined.

Results. MPO and NAβG were not considered very useful as biochemical predictors of muscle damage for these formulations. Histology generally correlated with RbLV values. Compared to saline, RbLV was marked for all formulations within 1–3 days of injection. After day 3, lesions quickly resolved, and no significant differences were found. For these formulations, all CK animal models and RFE were generally predictive of RbLV. A formulation with RtCK > 1000 U/L or RbCK > 3000 U/L, was predicted to be poorly, tolerated.

Conclusions. Due to ease, number of animals, time and intrinsic mechanism, we concluded that for most formulations, 2 and 4 hr RtCK data alone should be reasonably predictive of muscle damage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. Svendsen, O: Studies of Tissue Injuries Caused by Intramuscular Injection of Drugs and Vehicles, Thesis, Royal Veterinary and Agricultural University, Copenhagen, 1988.

  2. Gray, J. E.: In: Sustained and Controlled Release Delivery Systems, JR Robinson (ed.), Marcel Dekker, NY, 1978, pp. 351–410.

    Google Scholar 

  3. Gray, J. E.: Fund Appl Tox 1 290–292, 1981.

    Google Scholar 

  4. Surber C. and H. Sucker: Pharm Res 4:490–494, 1987.

    Google Scholar 

  5. Comereski C. R., P. D. Williams, C. L. Bregman and G. H. Hottendorf: Fund Appl Tox 6 335–338, 1986.

    Google Scholar 

  6. Anderson, K. E. and Damsgaard, T.: Acta med. scand. 199:317–319, 1976.

    Google Scholar 

  7. Meltzer H. Y., S. Mrozak, M. Boyer: Amer. J. Med. Sci. 259:42–48, 1970.

    Google Scholar 

  8. Steiness E., F. Rasmussen, O. Svendsen and P. Nielsen: Acta Pharmacol et Toxicol 42:357–364, 1978.

    Google Scholar 

  9. Svendsen O., F. Højelse and R. E. Bagdon: Acta Pharmacol et Toxicol 56:183–190, 1985.

    Google Scholar 

  10. Lefkowitz D. L., K. Mills, D. Morgan and S. S. Lefkowitz: Proc. Soc. Exp. Biol. Med. 199:204–210, 1992.

    Google Scholar 

  11. Pettipher E. R., B. Henderson, S. Moncada and G. A. Higgs: Br. J. Pharmacol. 95:169–76, 1988.

    Google Scholar 

  12. Szasz G., W. Gruber and E. Bernt: Clin. Chem. 22 650–656, 1976.

    Google Scholar 

  13. Brazeau G. A. and H.-L. Fung: Biochem J 257 619–621, 1989.

    Google Scholar 

  14. Miller M. J. S., H. Sadowska-Krowicka, S. Chotinaruemol, J. L. Kakkis and D. A. Clark: J. Pharmacol. Exp. Ther. 261 11–16, 1993.

    Google Scholar 

  15. Shintani S., M. Yamazaki, M. Nakamura and I. NakayamaL: Tax Appl Pharmacol 11 293–301, 1967.

    Google Scholar 

  16. Oshida S., K. Degawa, Y. Takahashi and S. Akaishi: Tnhoku J exp Med 127 301–316, 1979.

    Google Scholar 

  17. Steiness E., O. Svendsen and F. Rasmussen: Clin Pharmacol Ther 16 430–434, 1974.

    Google Scholar 

  18. Brazeau G. A. and H.-L. Fung: Pharm Res 6 167–170, 1989.

    Google Scholar 

  19. Brazeau, G. A. and H.-L. Fung: J Pharm Sci 79 393–397, 1990.

    Google Scholar 

  20. Svendsen, O.: Local muscle damage and oily vehicles: Acta pharmacol et. toxicol 52 298–304, 1983.

    Google Scholar 

  21. Brazeau, G., Gatlin, L. A., Jackson, M., Sutton, S. C., Gupta, P. K.: Symposium on The Evaluation of Pain, Irritation and Tissue Damage with Parenteral Formulations. AAPS Tenth Annual Meeting, Miami Beach, FL, 5–9 Nov., 1995.

  22. Greenblatt J., D. W. Duhme, M. Penna, T. Greiner and H. Gold: N Eng. J Med 288 651–654, 1973.

    Google Scholar 

  23. Meltzer, H.: Biochem. Pharmacol. 20 1739–1748, 1971.

    Google Scholar 

  24. Wamock, D. G. and G. L. Ellman: Science 164 726, 1969.

    Google Scholar 

  25. Paget and H McG Scott: Brit J Pharmacol 12 427–433, 1957.

    Google Scholar 

  26. Brazeau, G. A., S. S. Watts and L. S. Mathews: J Parent Sci Tech, 46 25–30, 1992.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical R & D Department, Central Research Division, Pfizer, Incorporated, Bldg. 156A Box 13, Groton, Connecticut, 06340

    Steven C. Sutton, Loreen A. F. Evans, Michelle T. S. Rinaldi & Kathy A. Norton

Authors
  1. Steven C. Sutton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Loreen A. F. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michelle T. S. Rinaldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kathy A. Norton
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sutton, S.C., Evans, L.A.F., Rinaldi, M.T.S. et al. Predicting Injection Site Muscle Damage I: Evaluation of Immediate Release Parenteral Formulations in Animal Models. Pharm Res 13, 1507–1513 (1996). https://doi.org/10.1023/A:1016075412098

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016075412098

Search

Navigation